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Abstract 
 
 
Bipolar disorder is a psychiatric disorder characterized by episodes of abnormally 
elevated mood followed by periods of extreme depression. Currently, valproate is one of 
the drugs used to treat the disorder but it is associated with many negative side effects.  
The goal of this project is to create a prodrug with structural similarities to valproate and 
determine if its effect on growth of the yeast Saccharomyces cerevisiae is similar to that 
of valproate.  Yeast cells were grown in media with or without the prodrug in the 
presence or absence of inositol.  The results showed that the prodrug inhibited growth.  
 
 
 
 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	   	   	  3	  
Background 
Bipolar disorder is a severe and chronic illness affecting approximately 1.5% of 
the American population (Azab et al., 2007; Azab and Miriam L. Greenberg, 2006). The 
major symptoms of the disorder are episodes of abnormally elevated mood followed by 
periods of extreme depression. One of the drugs currently used to treat patients with 
bipolar disorder is valproate. It is thought to accomplish treatment through the depletion 
of intracellular inositol. Inositol is a chemical compound that forms the basis of many 
second messenger systems in the body. A second messenger is a molecule that relays 
signals from receptors on the cell surface to target molecules within the cell, therefore 
causing a change in the activity of the cell. The original signal usually comes from a 
hormone.  
 Valproate is effective in managing the symptoms of bipolar disorder, as it is a 
mood stabilizer and anti-convulsant. However, there are many negative side effects 
associated with the drug. These include nausea, vomiting, diarrhea, indigestion, and in 
some rare cases, liver failure and pancreatitis. The purpose of this research project is to 
create a valproate prodrug and test its effect on the inositol biosynthetic pathway of the 
yeast Saccharomyces cerevisiae. To make a prodrug, an inactive group is attached to a 
known pharmacologically active molecule (in this case, valproate) via an easily 
metabolized ester linkage. The two inactive groups used in this project were an aldehyde 
and a chlorine atom. Activation of the prodrug is then achieved by the action of enzymes 
in the body. The reason for using a prodrug is to promote easier absorption and solubility, 
thereby minimizing the side effect while still treating the target symptoms.   
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The specific compound that will be made is called α-chlorooctyl valproate, which 
belongs to the organic family of α-haloacylals or 1-haloalkyl esters. This prodrug will 
then be tested for its ability to affect yeast growth of the strain SMY7 in the presence or 
absence of inositol. The success of the prodrug will depend on its ability to act similar to 
that of valproate by decreasing intracellular inositol. Yeast growth is dependent on 
inositol and therefore inhibited growth should indicate a decrease in inositol levels. The 
reason for using yeast as the biological system is that yeast and humans have a similar 
inositol biosynthetic pathway. Therefore, how the prodrug affects inositol levels in yeast 
will be indicative of how it possibly would affect inositol levels in humans and thus 
whether it is a viable option for the treatment of bipolar disorder. 
 
Methodology 
 
SYNTHESIS OF VALPROATE PRODRUG (α-CHLOROOCTYL VALPROATE): 
Trial 1 
A 50 mL round bottom flask and spin vane were dried in the oven for about 15 
minutes. Valproic acid (VPA) and thionyl chloride were refluxed for 45 minutes in 
dichloromethane to produce valproyl chloride. Reflux involves boiling the solution with 
minimal evaporation of the reactants, products and solvent. The valproyl chloride was 
then cooled in an ice bath and octyl aldehyde and zinc oxide (catalyst) were added to the 
mixture. This solution was stirred at room temperature for approximately two hours. The 
final mixture was gravity filtered and then rotovapped. Gravity filtration is used to isolate 
the desired product dissolved in the solvent away from the solid zinc oxide catalyst. 
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Rotary evaporation or rotavap is then used to ensure the removal of the solvent away 
from the product. Nuclear magnetic resonance (NMR) spectroscopy was then performed 
to analyze the resulting product. Table 1 provides the amounts of materials used in this 
trial.  
Table 1 
Compound Moles Volume 
(mL) 
Grams Density 
(g/mL) 
Molecular 
weight 
(g/mol) 
VPA 0.008 1.28 -- 0.90 144.21 
Octyl aldehyde 0.008 1.25 -- 0.82 128.22 
Thionyl chloride 0.009 0.66 -- 1.61 118.97 
Dichloromethane -- 20 -- -- -- 
Anhydrous zinc 
oxide 
0.002 -- 0.273 5.60 81.41 
 
Trial 2 
A 100 mL round bottom flask and spin vane were dried in the oven for about 15 
minutes. VPA and thionyl chloride were refluxed in dichloromethane for one hour to 
produce valproyl chloride. Reflux involves boiling the solution with minimal evaporation 
of the reactants, products and solvent. The valproyl chloride was then cooled in an ice 
bath and octyl aldehyde and zinc chloride (catalyst) were added. The solution was stirred 
at room temperature for approximately three hours. The final mixture was gravity filtered 
and then rotovapped. Gravity filtration is used to isolate the desired product dissolved in 
the solvent away from the solid zinc oxide catalyst. Rotary evaporation or rotavap is then 
used to ensure the removal of the solvent away from the product. After performing an 
NMR of the product, further purification was done through column chromatography. The 
solvent chosen was hexane and alumina gel was used as the adsorbent. The resulting 
fractions were rotovapped and analyzed using NMR to determine which fraction was 
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structurally similar to the desired product. Infrared (IR) spectroscopy was performed on 
the chosen fraction along with the starting materials (octyl aldehyde and VPA) for further 
analysis. Table 2 provides the amounts of materials used in this trial.  
Table 2 
Compound Moles Volume 
(mL) 
Grams Density 
(g/mL) 
Molecular 
weight 
(g/mol) 
VPA 0.024 3.846 -- 0.90 144.21 
Octyl aldehyde 0.024 3.744 -- 0.82 128.22 
Thionyl chloride 0.027 1.990 -- 1.61 118.97 
Dichloromethane -- 50 -- -- -- 
Anhydrous zinc 
chloride 
0.006 -- 0.665 -- 110.86 
 
BIOLOGICAL TESTING: 
Liquid media for the yeast was prepared using the ingredients in Table 3. Two 
types of media were made: one with inositol (I+) and one without inositol (I-). The 
ingredients for 500 mL of media were mixed into two 1 L Erlenmeyer flasks, labeled 
either I+ or I- depending on the contents. These flasks were then covered with aluminum 
foil and autoclaved for 25 minutes along with two empty 250 mL Erlenmeyer flasks each 
labeled either I+ or I-. Then, 100 mL each of the I+ and I- media was poured into its 
corresponding 250 mL flask. This was then inoculated with plated SMY7 yeast cells and 
allowed to grow for 24-30 hours in a shaker bath (150 rpm; 30 °C). After this, 1000 µl of 
stock I+ media was placed in a cuvette using a pipette as a control, 900 µl of stock I+ 
media was placed in a second cuvette as well as 100 µl from the I- overnight flask, and 
900 µl of stock I+ media was placed in a third cuvette as well as 100 µl from the I+ 
overnight flask. A concentration reading was then taken with the spectrophotometer to 
confirm that there was enough growth to continue on with next step (at least 0.1).  
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After autoclaving five new empty 250 mL Erlenmeyer flasks, each flask was 
labeled I+, I-, PD1, PD2, or PD3 (PD corresponds to prodrug). 100 mL of I+ media was 
added to the new I+ flask and 100 mL of I- media was added to each of the other four 
flasks. Based on calculations using the formula C1V1 = C2V2, specific volumes of the I+ 
and I- overnight solutions were added to the corresponding flasks containing new media. 
The prodrug flasks contained both I- overnight solution as well as certain concentrations 
of prodrug. PD1 had a prodrug concentration of 0.5 mM, PD2 had a concentration of 2.5 
mM, and PD3 had a concentration of 5.0 mM. These five flasks were placed in a shaker 
bath (150 rpm; 30 °C) for 24-30 hours. Another concentration reading was taken of the 
resulting cells using the spectrophotometer. A 10-5 dilution was then performed on the 
resulting solutions. 1 mL of each solution was placed in a cuvette, 10 µl of that was 
placed in another cuvette with 990 µl of water, 10 µl of that was placed in a third cuvette 
with 990 µl of water, and finally 100 µl of that was spread on a previously made YPD 
plate (see Table 4 for recipe). The plates were incubated for 48 hours and then the 
resulting yeast colonies were counted. 
Table 3 
Ingredient Amount 
Vitamin Free Yeast Base 0.345 mL 
Ammonium sulfate 1.005 mL 
Glucose 10 g 
100x vitamins 10 g 
Myo-inositol 5 mL 
Adenine 7.5 mL 
Arginine 1 mL 
Histidine 1 mL 
Leucine 2 mL 
Lysine 1 mL 
Methionine 1 mL 
Threonine 8 mL 
Tryptophan 1 mL 
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Uracil  8 mL 
Deionized H2O 500 mL 
 
Table 4 
Ingredient  Amount  
Yeast extract 10 g 
Bacto-peptone 20 g 
Glucose 20 g 
Agar 20 g 
Deionized H2O 1 L 
 
Results 
 
NMR and IR ANALYSIS:  
Table 5 summarizes the important spectral features that resulted from IR, 1H-NMR, and 
13C-NMR spectroscopy. The number of peaks refers either to the number of different 
hydrogens or carbons depending on the type of NMR performed.  
Table 5 
 Important Spectral Features 
Compound IR (cm-1) 1H-NMR (ppm) 13C-NMR (ppm) 
Octyl aldehyde C=O (1727) H1 (9.7) 
Ha (2.4) 
# of peaks* = 8 
Cα (44.0) 
C8 (14.0) 
# of peaks** = 8 
VPA C=O (1706) 
O-H (2961) 
C-O (1215,1253) 
Hb (2.35) 
# of peaks* = 5 
C1 (184.0) 
C2 (45.0) 
# of peaks** = 5 
α-chlorooctyl 
valproate (product) 
C=O (1758) 
C-O (1110) 
Ha (6.4) 
Hb (2.35) 
# of peaks* = 12 
C1 (174.5) 
C2 (45.0) 
Cα (84.0) 
C8 (14.0) 
# of peaks** = 13 
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BIOLOGICAL TESTING: 
Trial 1 
The following table shows the results of colony growth in Trial 1: 
Table 6 
Type of media Number of colonies 
With inositol (I+) 82 
Without inositol (I-) 101 
I- and Prodrug (0.5 mM) 1060 
I- and Prodrug (2.5 mM) 517 
I- and Prodrug (5.0 mM) 184 
 
Trial 2 
The following table shows results of colony growth in Trial 2: 
Table 7 
Type of media Number of colonies 
With inositol (I+) 85 
Without inositol (I-) 8 
I- and Prodrug (0.5 mM) 4 
I- and Prodrug (2.5 mM) 18 
I- and Prodrug (5.0 mM) 9 
 
Trial 3 
The following table shows results of colony growth in Trial 3: 
Table 8 
Type of media Number of colonies 
With inositol (I+) 468 
Without inositol (I-) 167 
I- and Prodrug (5.0 mM) 84 
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Discussion 
 
PRODRUG SYNTHESIS: 
The main differences between Trial 1 and 2 were the amounts of materials, the 
time required, and the catalyst used. The amount of moles used in Trial 1 were tripled for 
Trial 2 because there was not enough material produced from Trial 1 and therefore the 
experiment needed to be scaled up. As a result, the time required for each step needed to 
be altered to accommodate the greater volume of solutions. Also, the catalyst used in 
Trial 1 was zinc oxide while the catalyst used in Trial 2 was zinc chloride. The reason 
that zinc oxide was originally used was because it is easier to produce and not easily 
contaminated. Zinc chloride, on the other hand, is a strong catalyst but it requires more 
preparation and therefore is more susceptible to contamination. The product that resulted 
from Trial 1 was not exactly the desired product. This could have been due to the fact that 
the zinc oxide catalyst was not efficient enough to drive the reaction to completion. When 
the catalyst was switched to zinc chloride in Trial 2, the product came out with a structure 
similar to the expected product. Because Trial 1 resulted in a poor product, there was no 
further purification done. That is why column chromatography only appears in Trial 2.  
NMR and IR Analysis 
The IR of the prodrug showed two main diagnostic peaks that indicate the success of the 
reaction. There was a peak at 1758.42 cm-1 and at 1110.32 cm-1, which are both 
characteristic of an ester and thus the desired product. The 1H NMR of both the prodrug 
and VPA showed a peak at 2.35 ppm. This is because the specific hydrogen atom in VPA 
remained in the same position throughout the reaction and was therefore also present in 
the prodrug. The prodrug also shares a hydrogen atom with octyl aldehyde. However, in 
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the octyl aldehyde, it produced a peak at 2.4 ppm while in the prodrug, its peak was at 6.4 
ppm. This chemical shift was due to the fact that the reaction resulted in the hydrogen 
atom moving next to an oxygen atom and a chloride atom, both very electronegative 
groups. Finally, the 13C NMR confirmed the success of the reaction. Most of the carbon 
atoms in the octyl aldehyde and VPA stayed in relatively the same positions throughout 
the reaction. The main chemical shift occurred for the alpha carbon atom in the octyl 
aldehyde. It moved from next to an oxygen atom to next to an oxygen atom and a 
chloride atom. These electronegative groups attracted the electrons from the carbon atom, 
causing the shift in ppm.  
 
BIOLOGICAL TESTING: 
Ideally, the prediction was that plates containing I+ media should have the largest 
number of colonies. Cells need inositol to grow and therefore the addition of extra 
inositol in the I+ media should have led to increased growth. The plates with I- media and 
the prodrug were predicted to have less growth than the two control plates. This is 
because the cells would not be getting extra inositol from the media and the inositol made 
intracellularly should be depleted by the prodrug. Therefore, the lack of inositol should 
inhibit large amounts of growth. Increasing the concentration of the prodrug should result 
in a decrease of cell growth.  
As shown in Tables 6, 7, and 8, the results from the plating of the yeast cultures 
varied from trial to trial. Trial 1 resulted in the plate with cells grown in I- media and 0.5 
mM of prodrug having the most growth and the plate with cells grown in I+ media 
having the least growth. This pattern is most likely due to the fact that the plates were 
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contaminated before the cells could be counted and therefore cell growth was affected. 
The plates with the prodrug did, however, display the expected pattern that increasing 
prodrug concentration results in decreased cell growth. The results from Trial 2 showed 
that the I+ plate had the most growth, which was expected. Also, the fact that each 
prodrug plate had less growth than the I+ plate follows the prediction that the prodrug 
decreases cell growth by depleting intracellular inositol levels. The problem with Trial 2 
is that there isn’t a linear relationship between prodrug concentration and colony growth. 
Also, the two plates with the highest prodrug concentration have more growth than the I- 
plate, which is opposite to what should have happened. Finally, Trial 3 displayed a 
pattern that was most similar to the predicted pattern. The I+ plate had the most growth 
and the prodrug plate had the least growth. Unfortunately, there was not enough prodrug 
left to test three different concentrations so only the concentration of 5.0 mM was used in 
the trial as it was the most effective.  
 
Conclusion 
The prodrug synthesis was determined to be successful based on the NMR and IR 
analysis. The one problem with the synthesis was that not enough of the drug was 
produced. A solution for this would be to increase the starting amounts of materials. 
There would need to be more testing done for the results from the biological testing to be 
conclusive. Future experiments should include more trials in order to obtain a broader 
range of data.  
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  stabilizers	  such	  as	  lithium	  and	  valproate.	  It	  was	  shown	  that	  these	  drugs	  modulate	  the	  expression	  of	  several	  genes	  involved	  in	  inositol	  synthesis.	  Therefore,	  the	  regulation	  of	  signaling	  pathways	  plays	  a	  major	  role	  in	  the	  actions	  of	  lithium	  and	  valproate.	  This	  article	  is	  useful	  to	  my	  research	  because	  it	  not	  only	  explains	  the	  various	  mechanisms	  but	  it	  also	  describes	  the	  clinical	  implications	  of	  this	  study.	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  This	  article	  provides	  further	  evidence	  that	  lithium	  and	  valproate	  decrease	  cellular	  inositol	  by	  inhibiting	  either	  inositol	  monophosphatase	  or	  myo-­‐inositol-­‐1-­‐phosphate	  (MIP)	  synthase.	  This	  information	  was	  obtained	  through	  various	  experiments	  on	  yeast	  cells	  and	  rat	  neurons.	  The	  details	  of	  the	  experiments	  provide	  a	  good	  background	  for	  carrying	  out	  my	  own	  experiments	  and	  understanding	  the	  underlying	  mechanisms.	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  This	  article	  looks	  at	  the	  genetic	  mechanism	  behind	  the	  decrease	  in	  intracellular	  inositol	  by	  lithium	  and	  valproate.	  The	  goal	  of	  the	  authors	  is	  to	  determine	  the	  targets	  of	  valproate	  and	  lithium	  in	  the	  inositol	  metabolic	  pathway	  and	  they	  use	  the	  yeast	  Saccharomyces	  cerevisiae	  as	  a	  model	  for	  this.	  The	  study	  demonstrates	  that	  lithium	  and	  valproate	  affect	  common	  targets	  but	  deplete	  inositol	  by	  different	  mechanisms.	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  Since	  this	  article	  focuses	  on	  experiments	  using	  yeast,	  my	  research	  can	  benefit	  from	  this	  study	  by	  examining	  its	  methods	  and	  comparing	  the	  results	  to	  my	  own.	  	  	  	   	  
